Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials

29 recruiting

Pancreatic Ductal Adenocarcinoma (PDAC) Trials at a Glance

32 actively recruiting trials for pancreatic ductal adenocarcinoma (pdac) are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Fairfax, San Antonio, and New York. Lead sponsors running pancreatic ductal adenocarcinoma (pdac) studies include Revolution Medicines, Inc., BetaGlue Therapeutics SpA, and Beijing Biotech.

Browse pancreatic ductal adenocarcinoma (pdac) trials by phase

Treatments under study

About Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials

Looking for clinical trials for Pancreatic Ductal Adenocarcinoma (PDAC)? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Ductal Adenocarcinoma (PDAC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 2

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE105 enrolled10 locationsNCT07255404
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Not Applicable

Nutrition Intervention for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumors (pNET)
Children's Hospital of Philadelphia18 enrolled2 locationsNCT07554560
Recruiting
Phase 2

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited39 enrolled1 locationNCT07450859
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE200 enrolled10 locationsNCT07217717
Recruiting
Not Applicable

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neoplasms+1 more
ARTIDIS AG200 enrolled1 locationNCT07542041
Recruiting
Phase 2

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Pancreatic Ductal Adenocarcinoma (PDAC)
Institut Curie35 enrolled1 locationNCT06659705
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1Phase 2

The KN510713 Study in Combination With mFOLFIRINOX

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
New Cancer Cure-Bio Co.,Ltd.30 enrolled1 locationNCT07114861
Recruiting
Phase 1

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)
University of California, San Diego36 enrolled1 locationNCT06639724
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting

Advanced Therapies for Liver Metastases

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Liver Metastasis+1 more
IRCCS San Raffaele625 enrolled1 locationNCT04622423
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Phase 2

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Not Applicable

Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC

Pancreatic Ductal Adenocarcinoma (PDAC)Locally AdvancedUnresectable
BetaGlue Therapeutics SpA10 enrolled2 locationsNCT07155850
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

Pancreatic Ductal Adenocarcinoma (PDAC)
University of Colorado, Denver10 enrolled1 locationNCT07030283
Recruiting
Phase 2

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic NeoplasmsCancer of Pancreas+4 more
UNC Lineberger Comprehensive Cancer Center45 enrolled1 locationNCT03977233